New targeting tech makes for better vaccines says Vaccibody
A new vaccine targeting technology offers both therapeutic efficacy and manufacturing advantages according to developer Vaccibody.
Archives for November 14, 2012
EXCLUSIVE - update
Source bovine materials from BSE-free Australia or NZ: CEO's plea to regulators
Regulators should force pharmaceutical firms to source from BSE-safe countries according to Rocky Mountain Biologicals' CEO.
SAFC expands PharmaGrade raw material portfolio to meet demands
SAFC has added 25 new raw materials to its portfolio of PharmaGrade products, expanding its early phase material offering.
Fujifilm to make Thrombogenics' newly US approved eye drug in UK
Fujifilm Diosynth Biotechnologies will manufacture the bulk API for ThromboGenics recently US approved eye treatment Jetrea at its facility in Billingham in the UK.
CRO round-up: collaboration, expansions and small providers teaming-up to take on the big players
A new personalised medicine-focused partnership for AstraZeneca, expansion in three continents for World Wide clinical and six small CROs team-up to create one super-team. Outsourcing-pharma.com presents a round-up of the latest in clinical research...
Lack of harmonization on impurities a concern, says industry group
An industry consortium has asked the USP to delay new elemental impurities chapters on concerns that lack of harmonization with ICH Q3D will create compliance difficulties, shortages and additional costs.